Mutagen sensitivity and neoplastic progression in patients with Barrett's esophagus: A prospective analysis

Cancer Epidemiology Biomarkers and Prevention

Volumn 15, Issue 10, 2006, Pages 1935-1940

  Chao, Dennis L ^a   Maley, Carlo C ^c   Wu, Xifeng ^d   Farrow, Diana C ^a,b   Galipeau, Patricia C ^a   Sanchez, Carissa A ^a   Paulson, Thomas G ^a   Rabinovitch, Peter S ^a,b   Reid, Brian J ^a,b   Spitz, Margaret R ^d   Vaughan, Thomas L ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c WISTAR INSTITUTE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; MUTAGENIC AGENT; PROTEIN P16; PROTEIN P53;

ADULT; AGED; ANEUPLOIDY; ARTICLE; BARRETT ESOPHAGUS; CANCER RISK; CHROMOSOME 17Q; CONTROLLED STUDY; DISEASE COURSE; ENDOSCOPY; ESOPHAGEAL ADENOCARCINOMA; FEMALE; FOLLOW UP; GENE INACTIVATION; GENE LOCUS; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MUTAGEN TESTING; NEOPLASM; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ADULT; AGED; ANEUPLOIDY; ANTIBIOTICS, ANTINEOPLASTIC; BARRETT ESOPHAGUS; BLEOMYCIN; CHROMOSOME BREAKAGE; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 9; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION; GENES, P16; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; MUTAGENS; PRECANCEROUS CONDITIONS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 33750523998     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-06-0492     Document Type: Article

References (70)

1. Bollschweiler E, Wolfgarten E, Gutschow C, Hölscher AH. Demographic variations in the rising incidence of esophageal adenocarcinoma in White males. Cancer 2001;92:549-55.
2. Vizcaino AP, Moreno V, Lambert R, Parkin DM. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer 2002;99:860-8.
3. Brown LM, Devesa SS. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin N Am 2002;11:235-56.
4. Winters C, Jr., Spurling TJ, Chobanian SJ, et al. Barrett's esophagus, a prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 1987;92:118-24.
5. Lagergren J, Bergström R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31.
6. Falk GW. Gastroesophageal reflux disease and Barrett's esophagus. Endoscopy 2001;33:109-18.
7. Conio M, Filiberti R, Blanchi S, et al. Risk factors for Barrett's esophagus: a case-control study. Int J Cancer 2002;97:225-9.
8. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997;92:212-5.
9. O'Connor JB, Falk GW, Richter JE. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's esophagus registry. Am J Gastroenterol 1999;94:2037-42.
10. Conio M, Blanchi S, Lapertosa G, et al. Long-term endoscopic surveillance of patients with Barrett's esophagus, incidence of dysplasia and adenocarcinoma: a prospective study. Am J Gastroenterol 2003;98:1931-9.
11. Chow WH, Finkle WD, McLaughlin JK, Frankl H, Ziel HK, Fraumeni JF, Jr. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA 1995;274:474-7.
12. Coenraad M, Masclee AAM, Straathof JWA, Ganesh S, Griffioen G, Lamers CBHW. Is Barrett's esophagus characterized by more pronounced acid reflux than severe esophagitis? Am J Gastroenterol 1998;93:1068-72.
13. Farrow DC, Vaughan TL, Sweeney C, et al. Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes Control 2000;11:231-8.
14. Vaughan TL, Davis S, Kristal A, Thomas DB. Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 1995;4:85-92.
15. Brown LM, Swanson CA, Gridley G, et al. Adenocarcinoma of the esophagus: role of obesity and diet. J Natl Cancer Inst 1995;87:104-9.
16. Chow WH, Blot WJ, Vaughan TL, et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1998;90:150-5.
17. Lagergren J, Bergström R, Nyrén O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 1999;130:883-90.
18. Moe GL, Kristal AR, Levine DS, Vaughan TL, Reid BJ. Waist-to-hip ratio, weight gain, and dietary and serum selenium are associated with DNA content flow cytometry in Barrett's esophagus. Nutr Cancer 2000;36:7-13.
19. Kabat GC, Ng SK, Wynder EL. Tobacco, alcohol intake, and diet in relation to adenocarcinoma of the esophagus and gastric cardia. Cancer Causes Control 1993;4:123-32.
20. Brown LM, Silverman DT, Pottern LM, et al. Adenocarcinoma of the esophagus and esophagogastric junction in white men in the United States: alcohol, tobacco, and socioeconomic factors. Cancer Causes Control 1994;5:333-40.
21. Olliver JR, Hardie LJ, Dexter S, Chalmers D, Wild CP. DNA damage levels are raised in Barrett's oesophageal mucosa relative to the squamous epithelium of the oesophagus. Biomarkers 2003;8:509-21.
22. Olliver JR, Hardie LJ, Gong Y, et al. Risk factors, DNA damage, and disease progression in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2005;14:620-5.
23. Casson AG, Zheng Z, Evans SC, Veugelers PJ, Porter GA, Guernsey DL. Polymorphisms in DNA repair genes in the molecular pathogenesis of esophageal (Barrett) adenocarcinoma. Carcinogenesis 2005;26:1536-41.
24. Cherry LM, Hsu TC. Bleomycin-induced chromosome damage in lymphocytes of medullary thyroid carcinoma patients and their family members. Anticancer Res 1983;3:367-72.
25. Hsu TC, Johnston DA, Cherry LM, et al. Sensitivity to genotoxic effects of bleomycin in humans: possible relationship to environmental carcinogenesis. Int J Cancer 1989;43:403-9.
26. Berwick M, Vineis P. Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. J Natl Cancer Inst 2000;92:874-97.
27. Au WW. Mutagen sensitivity assays in population studies. Mutat Res 2003;544:273-7.
28. Schantz SP, Hsu TC. Mutagen-induced chromosome fragility within peripheral blood lymphocytes of head and neck cancer patients. Head Neck 1989;11:337-42.
29. Wu X, Hsu TC, Annegers JF, Amos CI, Fueger JJ, Spitz MR. A case-control study of nonrandom distribution of bleomycin-induced chromatid breaks in lymphocytes of lung cancer cases. Cancer Res 1995;55:557-61.
30. Wu X, Lippman SM, Lee JJ, et al. Chromosome instability in lymphocytes: a potential indicator of predisposition to oral premalignant lesions. Cancer Res 2002;62:2813-8.
31. Sturgis EM, Wei Q. Genetic susceptibility-molecular epidemiology of head and neck cancer. Curr Opin Oncol 2002;14:310-7.
32. Zheng YL, Loffredo CA, Yu Z, et al. Bleomycin-induced chromosome breaks as a risk marker for lung cancer: a case-control study with population and hospital controls. Carcinogenesis 2003;24:269-74.
33. Gajecka M, Jarmuz M, Szyfter W, Szyfter K. Non-random distribution of chromatid breaks in lymphocytes of laryngeal squamous cell carcinoma patients. Oncol Rep 2004;12:153-7.
34. Cloos J, Nieuwenhuis EJC, Boomsma DI, et al. Inherited susceptibility to bleomycin-induced chromatid breaks in cultured peripheral blood lymphocytes. J Natl Cancer Inst 1999;91:1125-30.
35. Yu GP, Zhang ZF, Hsu TC, Spitz MR, Schantz SP. Family history of cancer, mutagen sensitivity, and increased risk of head and neck cancer. Cancer Lett 1999;146:93-101.
36. Kowalska E, Narod SA, Huzarski T, et al. Increased rates of chromosome breakage in BRCA1 carriers are normalized by oral selenium supplementation. Cancer Epidemiol Biomarkers Prev 2005;14:1302-6.
37. Zhang ZF, Morgenstern H, Spitz MR, et al. Environmental tobacco smoking, mutagen sensitivity, and head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2000;9:1043-9.
38. King TM, Trizna Z, Wu X, et al. A clinical trial to evaluate the effect of vitamin C supplementation on in vitro mutagen sensitivity. The University of Texas M. D. Anderson Clinical Community Oncology Program Network. Cancer Epidemiol Biomarkers Prev 1997;6:537-42.
39. Székely G, Remenár E, Kásler M, Gundy S. Does the bleomycin sensitivity assay express cancer phenotype? Mutagenesis 2003;18:59-63.
40. Székely G, Remenár E, Kásler M, Gundy S. Mutagen sensitivity of patients with cancer at different sites of the head and neck. Mutagenesis 2005;20:381-5.
41. Spitz MR, Hoque A, Trizna Z, et al. Mutagen sensitivity as a risk factor for second malignant tumors following malignancies of the upper aerodigestive tract. J Natl Cancer Inst 1994;86:1681-4.
42. Spitz MR, Lippman SM, Jiang H, et al. Mutagen sensitivity as a predictor of tumor recurrence in patients with cancer of the upper aerodigestive tract. J Natl Cancer Inst 1998;90:243-5.
43. Cloos J, Leemans CR, van der Sterre MLT, Kuik DJ, Snow GB, Braakhuis BJM. Mutagen sensitivity as a biomarker for second primary tumors after head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2000;9:713-7.
44. Chang JY, Komaki R, Sasaki R, et al. High mutagen sensitivity in peripheral blood lymphocytes predicts poor overall and disease-specific survival in patients with stage III non-small cell lung cancer treated with radiotherapy and chemotherapy. Clin Cancer Res 2005;11:2894-8.
45. Barrett MT, Sanchez CA, Prevo LJ, et al. Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet 1999;22:106-9.
46. Jenkins GJS, Doak SH, Parry JM, D'Souza FR, Griffiths AP, Baxter JN. Genetic pathways involved in the progression of Barrett's metaplasia to adenocarcinoma. Br J Surg 2002;89:824-37.
47. Lukas J, Parry D, Aagaard L, et al. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 1995;375:503-6.
48. Poyurovsky MV, Prives C. Unleashing the power of p53: lessons from mice and men. Genes Dev 2006;20:125-31.
49. Reid BJ, Prevo LJ, Galipeau PC, et al. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 2001;96:2839-48.
50. Dolan K, Morris AI, Gosney JR, Field JK, Sutton R. Loss of heterozygosity on chromosome 17p predicts neoplastic progression in Barrett's esophagus. J Gastroenterol Hepatol 2003;18:683-9.
51. Dolan K, Walker SJ, Gosney J, Field JK, Sutton R. TP53 mutations in malignant and premalignant Barrett's esophagus. Dis Esophagus 2003;16:83-9.
52. Barrett MT, Sanchez CA, Galipeau PC, Neshat K, Emond M, Reid BJ. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. Oncogene 1996;13:1867-73.
53. Rabinovitch PS, Longton G, Blount PL, Levine DS, Reid BJ. Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. Am J Gastroenterol 2001;96:3071-83.
54. Teodori L, Gohde W, Persiani M, et al. DNA/protein flow cytometry as a predictive marker of malignancy in dysplasia-free Barrett's esophagus: thirteen-year follow-up study on a cohort of patients. Cytometry 1998;34:257-63.
55. Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low-and high-risk patient subsets. Am J Gastroenterol 2000;95:1669-76.
56. Reid BJ, Sanchez CA, Blount PL, Levine DS. Barrett's esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology 1993;105:119-29.
57. Blount PL, Galipeau PC, Sanchez CA, et al. 17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy. Cancer Res 1994;54:2292-5.
58. Paulson TG, Galipeau PC, Reid BJ. Loss of heterozygosity analysis using whole genome amplification, cell sorting, and fluorescence-based PCR. Genome Res 1999;9:482-91.
59. Galipeau PC, Prevo LJ, Sanchez CA, Longton GM, Reid BJ. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue. J Natl Cancer Inst 1999;91:2087-95.
60. Vaughan TL, Kristal AR, Blount PL, et al. Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2002;11:745-52.
61. Vaughan TL, Dong LM, Blount PL, et al. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol 2005;6:945-52.
62. R Development Core Team. R: a language and environment for statistical computing. Vienna (Austria): R Foundation for Statistical Computing; 2006.
63. Hoeijmakers JHJ. Genome maintenance mechanisms for preventing cancer. Nature 2001;411:366-74.
64. Herbst JJ, Berenson MM, McCloskey DW, Wiser WC. Cell proliferation in esophageal columnar epithelium (Barrett's esophagus). Gastroenterology 1978;75:683-7.
65. Pellish LJ, Hermos JA, Eastwood GL. Cell proliferation in three types of Barrett's epithelium. Gut 1980;21:26-31.
66. Gray MR, Hall PA, Nash J, Ansari B, Lane DP, Kingsnorth AN. Epithelial proliferation in Barrett's esophagus by proliferating cell nuclear antigen immunolocalization. Gastroenterology 1992;103:1769-76.
67. Blount PL, Meltzer SJ, Yin J, Huang Y, Krasna MJ, Reid BJ. Clonal ordering of 17p and 5q allelic losses in Barrett dysplasia and adenocarcinoma. Proc Natl Acad Sci U S A 1993;90:3221-5.
68. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev 1996;10:1054-72.
69. Vernole P, Tedeschi B, Tentori L, et al. Role of the mismatch repair system and p53 in the clastogenicity and cytotoxicity induced by bleomycin. Mutat Res 2006;594:63-77.
70. Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet 2001;27:247-54.